Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 388
interventional 351
Observational 36
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 174
Biological 27
Drug|Other 21
Biological|Drug 20
Biological|Drug|Other 19
Drug|placebo 16
Drug|Procedure 13
Procedure 10
Drug|Other|Procedure 8
Other 5
Biological|Drug|Procedure 4
Biological|Other 4
Behavioral 3
Device 3
Biological|Drug|Other|Procedure 2
Drug|Other|placebo 2
Drug|Radiation 2
Procedure|Radiation 2
Behavioral|Other 1
Behavioral|Other|Procedure 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Genetic|Other|Procedure 1
Biological|Drug|Other|placebo 1
Biological|Drug|placebo 1
Biological|Other|Procedure 1
Biological|placebo 1
Device|Drug 1
Device|Procedure 1
Dietary Supplement 1
Dietary Supplement|Drug|placebo 1
Dietary Supplement|Other|Procedure|Radiation 1
Drug|Other|Radiation 1
Drug|placebo|Radiation 1
Drug|Procedure|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 227
NA 11
United States|Canada 9
Canada 7
France 7
Germany 7
United Kingdom 7
China 5
Japan 4
Australia 2
Italy 2
Korea, Republic of 2
United States|Australia 2
Argentina|Austria|Belgium|Canada|Denmark|France|Germany|Ireland|Italy|Netherlands|Norway|Portugal|Spain|Sweden|United Kingdom 1
Australia|Austria|France|Italy|Netherlands|Portugal|Spain|United Kingdom 1
Australia|Belgium|Spain 1
Australia|France|Germany|Norway|United Kingdom 1
Australia|New Zealand|United Kingdom 1
Australia|Singapore 1
Austria|Belgium|China|Denmark|France|Germany|Italy|Korea, Republic of|Norway|Spain|Sweden|United Kingdom 1
Austria|Belgium|France|Germany|Italy 1
Austria|Belgium|France|Ireland|Italy|Netherlands|Portugal|South Africa|Spain|United Kingdom 1
Belarus|Belgium|Bulgaria|Croatia|Czech Republic|Denmark|Finland|Hungary|Latvia|Lithuania|Romania|Russian Federation|Serbia|Slovakia|Sweden|Ukraine 1
Belgium|Germany|Poland|Russian Federation|Spain 1
Belgium|Netherlands|Spain 1
Brazil 1
Canada|New Zealand|United Kingdom 1
Canada|United Kingdom 1
China|Korea, Republic of 1
Denmark|France|Germany|Norway 1
Finland 1
Germany|Denmark|Finland|France|Norway|Sweden 1
Israel 1
Israel|New Zealand|China|United States|Australia|Poland|Russian Federation|South Africa|Switzerland|United Kingdom 1
Japan|Korea, Republic of 1
Netherlands 1
Slovakia|United States|Canada|Netherlands|United Kingdom 1
Spain 1
United States|Australia|Austria|Belgium|Brazil|China|Czechia|Denmark|Finland|France|Germany|Greece|Israel|Italy|Japan|Korea, Republic of|Norway|Poland|Russian Federation|Spain|Sweden|Turkey 1
United States|Australia|Austria|Belgium|Canada|Czechia|Denmark|Finland|France|Germany|Hungary|Ireland|Italy|Luxembourg|Netherlands|Norway|Poland|Spain|Sweden|United Kingdom 1
United States|Australia|Belgium 1
United States|Australia|Belgium|Brazil|Bulgaria|Canada|Chile|Croatia|Czech Republic|Estonia|France|Greece|Hong Kong|India|Israel|Italy|Japan|Korea, Republic of|Latvia|Malaysia|Mexico|Peru|Poland|Portugal|Romania|Russian Federation|Slovenia|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|Chile|Colombia|Czechia|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Poland|Russian Federation|South Africa|Spain|Taiwan|Turkey|Ukraine 1
United States|Australia|Belgium|Canada|Denmark|Finland|Greece|Ireland|Israel|Italy|Japan|Korea, Republic of|New Zealand|Poland|Romania|Russian Federation|Singapore|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Israel|Italy|New Zealand|Spain|United Kingdom 1
United States|Australia|Belgium|Germany 1
United States|Australia|Belgium|Italy|Poland|Spain|United Kingdom 1
United States|Australia|Canada|Denmark|Finland|France|Greece|Italy|Poland|South Africa|Spain|United Kingdom 1
United States|Australia|Canada|France|Spain|United Kingdom 1
United States|Australia|Singapore 1
United States|Belgium|Bosnia and Herzegovina|Canada|Czechia|France|Ireland|Italy|Russian Federation|Serbia|Spain|Switzerland|United Kingdom 1
United States|Belgium|Canada|Denmark|Israel|Italy|Netherlands|Norway|Portugal|Spain 1
United States|Belgium|Canada|Spain 1
United States|Brazil|Canada|Czechia|Hungary|Israel|Italy|Poland|Russian Federation|Spain|Ukraine|United Kingdom 1
United States|Canada|Israel|Spain|United Kingdom 1
United States|Canada|Japan|Korea, Republic of 1
United States|Canada|Korea, Republic of 1
United States|Canada|Singapore 1
United States|Canada|Spain|United Kingdom 1
United States|Denmark|United Kingdom 1
United States|France 1
United States|France|Netherlands|Spain 1
United States|Germany 1
United States|Hong Kong|Japan|Korea, Republic of|New Zealand|Singapore 1
United States|Italy|Russian Federation 1
United States|Japan 1
United States|Japan|Korea, Republic of 1
United States|Korea, Republic of 1
United States|Norway 1
United States|Puerto Rico 1
United States|Spain 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 148
2 25
3 16
4 15
5 14
6 7
7 9
8 10
9 4
10 7
11 6
12 5
13 4
14 3
15 2
16 7
17 4
18 2
19 4
20 1
21 2
22 3
23 1
27 1
28 3
30 2
33 1
37 1
38 1
41 1
46 1
50 1
55 1
61 1
62 1
65 1
70 2
75 1
78 1
81 1
84 1
86 1
88 1
90 1
92 1
93 1
96 1
104 1
116 1
131 2
136 1
137 1
142 2
149 1
155 1
196 1
206 1
214 1
225 1
252 1
271 1
315 1
390 1
503 1
538 1
573 1
632 1
687 1
718 1

Phase

Phase Study_Count
Phase 2 141
Phase 1 96
Phase 3 48
Phase 1/Phase 2 32
N/A 18
Early Phase 1 12
Phase 2/Phase 3 4

Number of Arms

Number_of_Arms Count_of_Studies
1 150
2 101
3 19
4 14
5 1
6 2
7 1
8 1
NA 62

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3
Min. 10.00000 20.0000 7.00000 3.00 1.00000 107.00 34.0000
1st Qu. 17.00000 40.7500 18.00000 38.25 35.00000 139.25 255.2500
Median 29.50000 77.5000 28.00000 69.00 56.00000 150.00 637.0000
Mean 30.83333 120.8333 54.19767 100.80 79.79365 265.25 677.1087
3rd Qu. 34.75000 145.0000 45.50000 128.00 100.00000 276.00 1003.0000
Max. 75.00000 500.0000 588.00000 366.00 493.00000 654.00 1873.0000

Trial Group Type

group_type Group_Count
Experimental 398
Active Comparator 64
NA 62
Placebo Comparator 17
Other 13
No Intervention 5

Intervention Model

intervention_model Study_Count
Single Group Assignment 168
Parallel Assignment 117
NA 49
Sequential Assignment 11
Crossover Assignment 5
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 326
Supportive Care 11
Other 5
Prevention 4
Diagnostic 3
Basic Science 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
United States 22
United Kingdom 5
India 2
Canada|Italy|Spain|United Kingdom 1
Denmark 1
Denmark|Sweden 1
Egypt 1
Finland 1
Japan 1
Russian Federation 1

Sites per Study

Site_count Study_Count
1 23
3 1
4 2
6 1
8 1
10 1
22 2
111 1
144 1
182 1
187 1
358 1

Enrollment Metrics

Measure Observational
Min 19.0000
1st Qu 65.0000
Median 124.0000
Mean 421.6667
3rd Qu 254.0000
Max 6000.0000

Observation Model

observational_model Study_Count
Cohort 24
Case-Only 4
NA 4
Case-Control 2
Case-Crossover 1
Case Control 1

Time Perspective

time_perspective Study_Count
Prospective 26
Retrospective 4
NA 3
Other 2
Cross-Sectional 1

Registries

Studies by Country

Country Study_Count
France 1

Sites per Study

Site_count Study_Count
110 1

Enrollment Metrics

Measure Registries
Min 32
1st Qu 32
Median 32
Mean 32
3rd Qu 32
Max 32

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 1

Follow-up

target_duration Study_Count
10 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03311334 A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03311334 Recruiting Boston Biomedical, Inc 2021-11-30
NCT03029403 Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT03029403 Recruiting University Health Network, Toronto 2023-02-12
NCT04440943 A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies https://ClinicalTrials.gov/show/NCT04440943 Recruiting Celldex Therapeutics 2022-03-31
NCT04415944 Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy https://ClinicalTrials.gov/show/NCT04415944 Recruiting Wake Forest University Health Sciences 2021-01-31
NCT04019288 AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT04019288 Recruiting M.D. Anderson Cancer Center 2020-09-30
NCT03657043 A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) https://ClinicalTrials.gov/show/NCT03657043 Recruiting Seattle Genetics, Inc. 2022-08-31
NCT03393884 Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2) https://ClinicalTrials.gov/show/NCT03393884 Active, not recruiting Celsion 2022-02-28
NCT03378128 Debulking Surgery in Ovarian Cancer https://ClinicalTrials.gov/show/NCT03378128 Recruiting Case Comprehensive Cancer Center 2020-08-31
NCT03373058 Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery https://ClinicalTrials.gov/show/NCT03373058 Recruiting Affiliated Cancer Hospital & Institute of Guangzhou Medical University 2021-07-01
NCT03824704 A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) https://ClinicalTrials.gov/show/NCT03824704 Active, not recruiting Clovis Oncology, Inc. 2021-01-31
NCT03363867 BEACON - ABC in Recurrent Platinum Resistant HGSOC https://ClinicalTrials.gov/show/NCT03363867 Recruiting Peter MacCallum Cancer Centre, Australia 2022-07-01
NCT03326193 Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy https://ClinicalTrials.gov/show/NCT03326193 Active, not recruiting Tesaro, Inc. 2020-12-24
NCT03321188 Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients https://ClinicalTrials.gov/show/NCT03321188 Recruiting University of Kansas Medical Center 2020-12-15
NCT03283943 PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. https://ClinicalTrials.gov/show/NCT03283943 Recruiting British Columbia Cancer Agency 2020-12-16
NCT03213964 Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int https://ClinicalTrials.gov/show/NCT03213964 Recruiting Masonic Cancer Center, University of Minnesota 2025-01-01
NCT03188432 Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03188432 Recruiting Wake Forest University Health Sciences 2020-11-01
NCT03188159 Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer https://ClinicalTrials.gov/show/NCT03188159 Recruiting National University Hospital, Singapore 2021-07-01
NCT03150121 Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage https://ClinicalTrials.gov/show/NCT03150121 Recruiting Sheba Medical Center 2022-12-31
NCT03126812 Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer https://ClinicalTrials.gov/show/NCT03126812 Recruiting The Netherlands Cancer Institute 2020-06-30
NCT03113487 P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT03113487 Recruiting City of Hope Medical Center 2021-01-06
NCT03056833 Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer https://ClinicalTrials.gov/show/NCT03056833 Recruiting University of Pittsburgh 2020-06-01
NCT03054909 IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer https://ClinicalTrials.gov/show/NCT03054909 Recruiting Masonic Cancer Center, University of Minnesota 2020-12-31
NCT03054298 CAR T Cells in Mesothelin Expressing Cancers https://ClinicalTrials.gov/show/NCT03054298 Recruiting University of Pennsylvania 2021-03-31
NCT03030287 A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT03030287 Completed OncoMed Pharmaceuticals, Inc. 2020-04-30
NCT03026062 Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT03026062 Recruiting M.D. Anderson Cancer Center 2021-03-31
NCT02948426 Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02948426 Recruiting National Institutes of Health Clinical Center (CC) 2022-04-01
NCT02915523 Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT02915523 Active, not recruiting Syndax Pharmaceuticals 2019-07-31
NCT02903771 Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. https://ClinicalTrials.gov/show/NCT02903771 Completed Kazia Therapeutics Limited 2020-03-24
NCT02884648 Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery https://ClinicalTrials.gov/show/NCT02884648 Recruiting M.D. Anderson Cancer Center 2020-11-30
NCT02873962 A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib https://ClinicalTrials.gov/show/NCT02873962 Recruiting Dana-Farber Cancer Institute 2020-08-31
NCT02865811 Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02865811 Active, not recruiting Dana-Farber Cancer Institute 2021-02-28
NCT02859038 Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) https://ClinicalTrials.gov/show/NCT02859038 Recruiting Shanghai Gynecologic Oncology Group 2022-12-31
NCT02853318 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02853318 Active, not recruiting Roswell Park Cancer Institute 2020-08-03
NCT02786524 Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy https://ClinicalTrials.gov/show/NCT02786524 Completed University of Michigan 2017-10-31
NCT02785250 Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer https://ClinicalTrials.gov/show/NCT02785250 Active, not recruiting ImmunoVaccine Technologies, Inc. (IMV Inc.) 2020-02-29
NCT02759588 GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer https://ClinicalTrials.gov/show/NCT02759588 Recruiting Genelux Corporation 2020-07-31
NCT02728830 A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers https://ClinicalTrials.gov/show/NCT02728830 Active, not recruiting Duke University 2019-01-31
NCT02728622 Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane https://ClinicalTrials.gov/show/NCT02728622 Completed Nordic Society of Gynaecological Oncology - Clinical Trials Unit 2008-01-31
NCT02726997 Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) https://ClinicalTrials.gov/show/NCT02726997 Active, not recruiting M.D. Anderson Cancer Center 2021-07-30
NCT02725489 Pilot Study of Durvalumab and Vigil in Advanced Women’s Cancers https://ClinicalTrials.gov/show/NCT02725489 Active, not recruiting Mary Crowley Medical Research Center 2019-12-30
NCT02713386 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02713386 Active, not recruiting NRG Oncology 2020-09-30
NCT02659241 Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02659241 Recruiting M.D. Anderson Cancer Center 2021-12-31
NCT02658214 Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT02658214 Completed AstraZeneca 2019-11-14
NCT02657889 Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer https://ClinicalTrials.gov/show/NCT02657889 Active, not recruiting Tesaro, Inc. 2018-05-31
NCT02631876 A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT02631876 Completed ImmunoGen, Inc. 2019-01-31
NCT02627443 Carboplatin, Gemcitabine Hydrochloride, and ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT02627443 Recruiting National Cancer Institute (NCI) 2020-11-30
NCT02606305 Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab, Carboplatin, PLD, Pembrolizumab, or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT02606305 Active, not recruiting ImmunoGen, Inc. 2021-01-31
NCT02595892 Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT02595892 Active, not recruiting National Cancer Institute (NCI) 2021-03-19
NCT02650986 Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 https://ClinicalTrials.gov/show/NCT02650986 Recruiting Roswell Park Cancer Institute 2021-06-20
NCT01749397 Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01749397 Completed National Cancer Institute (NCI) 2017-10-20
NCT03038100 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03038100 Active, not recruiting Hoffmann-La Roche 2020-03-30
NCT02571725 PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer https://ClinicalTrials.gov/show/NCT02571725 Recruiting New Mexico Cancer Care Alliance 2020-02-29
NCT01970722 Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01970722 Recruiting City of Hope Medical Center 2021-05-19
NCT02520154 Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT02520154 Recruiting M.D. Anderson Cancer Center 2020-07-31
NCT02498600 Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT02498600 Active, not recruiting National Cancer Institute (NCI) 2018-09-05
NCT02489006 A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT02489006 Recruiting University Health Network, Toronto 2021-06-30
NCT02480374 Study of Safety & Biological Activity of IP GEN-1 With Neoadjuvant Chemo in Ovarian Cancer https://ClinicalTrials.gov/show/NCT02480374 Active, not recruiting Celsion 2017-06-30
NCT02470299 Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients https://ClinicalTrials.gov/show/NCT02470299 Completed New Mexico Cancer Care Alliance 2018-10-08
NCT02444195 Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients https://ClinicalTrials.gov/show/NCT02444195 Completed University of Michigan 2016-05-01
NCT02433626 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies https://ClinicalTrials.gov/show/NCT02433626 Recruiting Critical Outcome Technologies Inc. 2019-12-31
NCT02364713 MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02364713 Recruiting Mayo Clinic 2027-03-17
NCT02349958 Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy https://ClinicalTrials.gov/show/NCT02349958 Recruiting Bay Area Gynecology Oncology 2022-01-31
NCT02324439 Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission https://ClinicalTrials.gov/show/NCT02324439 Recruiting Southern Illinois University 2021-07-31
NCT02316834 Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02316834 Active, not recruiting M.D. Anderson Cancer Center 2021-02-01
NCT02312245 Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT02312245 Recruiting Mayo Clinic 2020-06-30
NCT02311907 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02311907 Completed Alliance for Clinical Trials in Oncology 2012-08-31
NCT02262455 Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT02262455 Completed Santa Maria Biotherapeutics 2017-01-13
NCT02142803 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT02142803 Active, not recruiting National Cancer Institute (NCI) 2020-06-30
NCT02125513 Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT02125513 Recruiting Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi 2020-08-31
NCT02124421 HOT: HIPEC in Ovarian Cancer as Initial Treatment https://ClinicalTrials.gov/show/NCT02124421 Recruiting Mercy Medical Center 2020-04-30
NCT02122185 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02122185 Recruiting University of Chicago 2021-02-25
NCT02121990 Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT02121990 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-04-30
NCT02111941 Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy https://ClinicalTrials.gov/show/NCT02111941 Active, not recruiting Mayo Clinic 2017-08-18
NCT02101775 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT02101775 Active, not recruiting National Cancer Institute (NCI) 2020-12-01
NCT01314105 BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01314105 Completed Boehringer Ingelheim 2013-07-31
NCT01313078 Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01313078 Completed National Institutes of Health Clinical Center (CC) 2011-09-30
NCT01312389 A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01312389 Completed Abramson Cancer Center of the University of Pennsylvania 2012-05-31
NCT01308944 Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients https://ClinicalTrials.gov/show/NCT01308944 Completed Washington University School of Medicine 2014-08-31
NCT01306032 Phase II ABT-888 With Cyclophosphamide https://ClinicalTrials.gov/show/NCT01306032 Completed National Institutes of Health Clinical Center (CC) 2014-12-31
NCT01281514 A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer https://ClinicalTrials.gov/show/NCT01281514 Completed Fox Chase Cancer Center 2018-01-08
NCT02046421 Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02046421 Completed University of Chicago 2018-05-31
NCT02042430 Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02042430 Active, not recruiting National Cancer Institute (NCI) 2016-03-31
NCT03093155 Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab https://ClinicalTrials.gov/show/NCT03093155 Active, not recruiting Yale University 2021-02-28
NCT02020707 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers https://ClinicalTrials.gov/show/NCT02020707 Recruiting Mayo Clinic 2020-10-03
NCT04296890 A Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression https://ClinicalTrials.gov/show/NCT04296890 Recruiting ImmunoGen, Inc. 2021-07-31
NCT03355976 BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas https://ClinicalTrials.gov/show/NCT03355976 Recruiting Brown University 2020-02-29
NCT03329950 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies https://ClinicalTrials.gov/show/NCT03329950 Recruiting Celldex Therapeutics 2021-08-31
NCT01974765 Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies https://ClinicalTrials.gov/show/NCT01974765 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-10-31
NCT01968213 A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01968213 Active, not recruiting Clovis Oncology, Inc. 2017-04-30
NCT01940172 Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer https://ClinicalTrials.gov/show/NCT01940172 Completed TetraLogic Pharmaceuticals 2015-09-30
NCT01905163 Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients https://ClinicalTrials.gov/show/NCT01905163 Completed Centre Jean Perrin 2016-08-31
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) https://ClinicalTrials.gov/show/NCT01891344 Active, not recruiting Clovis Oncology, Inc. 2019-11-05
NCT01849874 A Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01849874 Active, not recruiting Pfizer 2016-04-01
NCT01846611 A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01846611 Completed Janssen Research & Development, LLC 2018-01-18
NCT01767675 Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01767675 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-01-31
NCT01764802 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer https://ClinicalTrials.gov/show/NCT01764802 Completed Ohio State University Comprehensive Cancer Center 2017-06-01
NCT01764789 Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer https://ClinicalTrials.gov/show/NCT01764789 Completed Ohio State University Comprehensive Cancer Center 2012-01-31
NCT01747798 Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01747798 Completed Mayo Clinic 2014-01-10
NCT01704651 Accelerating Gastrointestinal Recovery https://ClinicalTrials.gov/show/NCT01704651 Completed Mayo Clinic 2015-08-31
NCT01670799 Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01670799 Completed New Mexico Cancer Care Alliance 2015-12-31
NCT01669798 BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT01669798 Completed Duke University 2017-09-10
NCT01669226 First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer https://ClinicalTrials.gov/show/NCT01669226 Completed Shanghai Gynecologic Oncology Group 2015-09-30
NCT01666444 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01666444 Completed Celgene 2016-07-31
NCT01663857 A Study LY2228820 for Recurrent Ovarian Cancer https://ClinicalTrials.gov/show/NCT01663857 Completed Eli Lilly and Company 2017-05-25
NCT01652794 Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer https://ClinicalTrials.gov/show/NCT01652794 Completed Case Comprehensive Cancer Center 2014-05-31
NCT01652079 CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01652079 Completed Massachusetts General Hospital 2018-03-31
NCT01649336 A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01649336 Completed Array BioPharma 2016-03-31
NCT01626014 Interactive Educational Website for Women With Ovarian Cancer & Caregivers https://ClinicalTrials.gov/show/NCT01626014 Completed University of Minnesota 2014-12-31
NCT01610869 Low Dose Cyclophosphamide +/– Nintedanib in Advanced Ovarian Cancer https://ClinicalTrials.gov/show/NCT01610869 Completed University College, London 2018-01-11
NCT01610206 A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer https://ClinicalTrials.gov/show/NCT01610206 Active, not recruiting University of Virginia 2018-06-01
NCT01606241 Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01606241 Completed Mayo Clinic 2014-09-25
NCT01556841 The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer https://ClinicalTrials.gov/show/NCT01556841 Completed University College, London 2019-04-19
NCT01536054 Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT01536054 Completed Roswell Park Cancer Institute 2015-04-21
NCT01506856 Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial https://ClinicalTrials.gov/show/NCT01506856 Active, not recruiting Gynecologic Oncology Trial & Investigation Consortium 2019-11-30
NCT01504126 Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01504126 Completed M.D. Anderson Cancer Center 2019-08-15
NCT01482715 A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) https://ClinicalTrials.gov/show/NCT01482715 Completed Clovis Oncology, Inc. 2019-03-31
NCT01478685 A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01478685 Completed Celgene 2015-11-17
NCT01462890 Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT01462890 Active, not recruiting AGO Study Group 2018-11-30
NCT01459380 Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01459380 Completed National Cancer Institute (NCI) 2016-06-08
NCT01447706 A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers https://ClinicalTrials.gov/show/NCT01447706 Completed Merrimack Pharmaceuticals 2013-09-30
NCT01442051 Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer https://ClinicalTrials.gov/show/NCT01442051 Completed Memorial Sloan Kettering Cancer Center 2019-07-01
NCT01416038 Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01416038 Completed ImmunoVaccine Technologies, Inc. (IMV Inc.) 2013-05-31
NCT01402271 Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01402271 Active, not recruiting European Organisation for Research and Treatment of Cancer - EORTC 2019-05-15
NCT01391351 Search for Predictors of Therapeutic Response in Ovarian Carcinoma https://ClinicalTrials.gov/show/NCT01391351 Completed Centre Francois Baclesse 2015-11-30
NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression https://ClinicalTrials.gov/show/NCT04209855 Recruiting ImmunoGen, Inc. 2022-06-30
NCT04267575 Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites https://ClinicalTrials.gov/show/NCT04267575 Recruiting Jerome Canady Research Institute for Advanced Biological & Technological Sciences 2020-07-30
NCT04213794 Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study https://ClinicalTrials.gov/show/NCT04213794 Recruiting Mayo Clinic 2025-01-30
NCT04158336 A Study of ZN-c3 in Participants With Solid Tumors https://ClinicalTrials.gov/show/NCT04158336 Recruiting K-Group Beta 2023-05-31
NCT04034927 Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT04034927 Recruiting National Cancer Institute (NCI) 2022-12-31
NCT04029909 A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT04029909 Recruiting Lee’s Pharmaceutical Limited 2019-12-31
NCT04025216 A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers https://ClinicalTrials.gov/show/NCT04025216 Recruiting Tmunity Therapeutics 2022-12-31
NCT04001023 Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia https://ClinicalTrials.gov/show/NCT04001023 Recruiting Turku University Hospital 2022-12-31
NCT03983226 Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) https://ClinicalTrials.gov/show/NCT03983226 Recruiting Shanghai Gynecologic Oncology Group 2023-06-30
NCT03976999 Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers https://ClinicalTrials.gov/show/NCT03976999 Recruiting Institut du Cancer de Montpellier - Val d’Aurelle 2020-07-31
NCT03968406 Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers https://ClinicalTrials.gov/show/NCT03968406 Recruiting M.D. Anderson Cancer Center 2021-10-11
NCT03943173 Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery https://ClinicalTrials.gov/show/NCT03943173 Recruiting M.D. Anderson Cancer Center 2021-03-03
NCT03922776 Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer https://ClinicalTrials.gov/show/NCT03922776 Recruiting Centre Oscar Lambret 2019-09-30
NCT03907527 Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03907527 Recruiting Fred Hutchinson Cancer Research Center 2022-04-01
NCT03849469 A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03849469 Recruiting Xencor, Inc. 2026-09-30
NCT03839524 A Trial Evaluating TG4050 in Ovarian Carcinoma. https://ClinicalTrials.gov/show/NCT03839524 Recruiting Transgene 2021-12-31
NCT03783949 European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer https://ClinicalTrials.gov/show/NCT03783949 Active, not recruiting Universitaire Ziekenhuizen Leuven 2021-03-31
NCT03771651 Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube https://ClinicalTrials.gov/show/NCT03771651 Recruiting University of Oklahoma 2021-03-01
NCT03759587 Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer https://ClinicalTrials.gov/show/NCT03759587 Active, not recruiting Takeda 2019-03-17
NCT03748186 Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers https://ClinicalTrials.gov/show/NCT03748186 Recruiting Sutro Biopharma, Inc. 2022-08-31
NCT03693248 Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03693248 Recruiting Seoul National University Hospital 2023-12-31
NCT03691376 Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03691376 Recruiting Roswell Park Cancer Institute 2020-10-01
NCT03648489 Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) https://ClinicalTrials.gov/show/NCT03648489 Recruiting Imperial College London 2022-03-31
NCT03635489 A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03635489 Active, not recruiting Hoffmann-La Roche 2020-12-29
NCT03604315 Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF https://ClinicalTrials.gov/show/NCT03604315 Recruiting M.D. Anderson Cancer Center 2022-12-31
NCT03586661 Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT03586661 Recruiting M.D. Anderson Cancer Center 2021-04-30
NCT03585764 MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03585764 Recruiting University of Pennsylvania 2020-10-31
NCT03564340 Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer https://ClinicalTrials.gov/show/NCT03564340 Recruiting Regeneron Pharmaceuticals 2022-05-11
NCT03540017 HIPEC After Initial CRS in Patients Who Have Received NACT https://ClinicalTrials.gov/show/NCT03540017 Recruiting Northwell Health 2020-07-05
NCT03522246 A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy https://ClinicalTrials.gov/show/NCT03522246 Recruiting Clovis Oncology, Inc. 2024-12-30
NCT03519178 A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy https://ClinicalTrials.gov/show/NCT03519178 Recruiting Pfizer 2023-03-19
NCT03508570 Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis https://ClinicalTrials.gov/show/NCT03508570 Recruiting M.D. Anderson Cancer Center 2021-01-01
NCT03462212 Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer. https://ClinicalTrials.gov/show/NCT03462212 Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 2018-11-01
NCT03430700 Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT03430700 Recruiting University College, London 2020-11-16
NCT01262040 Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive https://ClinicalTrials.gov/show/NCT01262040 Completed Memorial Sloan Kettering Cancer Center 2018-10-29
NCT01253681 Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer https://ClinicalTrials.gov/show/NCT01253681 Completed Amgen 2012-10-31
NCT01248962 Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01248962 Completed Memorial Sloan Kettering Cancer Center 2018-08-31
NCT01237067 Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers https://ClinicalTrials.gov/show/NCT01237067 Completed National Institutes of Health Clinical Center (CC) 2014-11-16
NCT01223235 Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab https://ClinicalTrials.gov/show/NCT01223235 Completed Memorial Sloan Kettering Cancer Center 2017-09-30
NCT01220154 Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer https://ClinicalTrials.gov/show/NCT01220154 Active, not recruiting Ohio State University Comprehensive Cancer Center 2021-03-31
NCT01219777 Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel for Primary Ovarian https://ClinicalTrials.gov/show/NCT01219777 Completed Ohio State University Comprehensive Cancer Center 2012-05-31
NCT01209195 A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers https://ClinicalTrials.gov/show/NCT01209195 Completed Merrimack Pharmaceuticals 2014-05-31
NCT01204749 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01204749 Completed Amgen 2013-03-31
NCT01196741 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer https://ClinicalTrials.gov/show/NCT01196741 Completed University College, London 2012-11-30
NCT01196559 Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer https://ClinicalTrials.gov/show/NCT01196559 Completed The Catholic University of Korea 2014-10-31
NCT01188876 Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01188876 Completed Massachusetts General Hospital 2016-07-31
NCT01175343 RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01175343 Completed National Cancer Institute (NCI) 2012-10-31
NCT01170299 Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer https://ClinicalTrials.gov/show/NCT01170299 Completed National Cancer Institute (NCI) 2012-12-31
NCT01167712 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01167712 Active, not recruiting National Cancer Institute (NCI) 2015-12-01
NCT01166737 Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer https://ClinicalTrials.gov/show/NCT01166737 Active, not recruiting AGO Study Group 2019-12-31
NCT01105650 Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer https://ClinicalTrials.gov/show/NCT01105650 Completed Masonic Cancer Center, University of Minnesota 2014-04-30
NCT01097746 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01097746 Active, not recruiting M.D. Anderson Cancer Center 2020-04-30
NCT01091428 Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer https://ClinicalTrials.gov/show/NCT01091428 Completed Takeda 2014-08-12
NCT01091259 Irinotecan and Bevacizumab for Recurrent Ovarian Cancer https://ClinicalTrials.gov/show/NCT01091259 Completed NYU Langone Health 2014-02-28
NCT01081262 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01081262 Active, not recruiting National Cancer Institute (NCI) 2015-02-25
NCT01079832 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies https://ClinicalTrials.gov/show/NCT01079832 Completed Case Comprehensive Cancer Center 2012-05-31
NCT01074411 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01074411 Completed National Cancer Institute (NCI) 2014-04-04
NCT01065662 AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies https://ClinicalTrials.gov/show/NCT01065662 Active, not recruiting Dana-Farber Cancer Institute 2013-09-30
NCT01031381 Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01031381 Completed University of Pittsburgh 2014-01-31
NCT01010126 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer https://ClinicalTrials.gov/show/NCT01010126 Completed National Cancer Institute (NCI) 2017-03-13
NCT01001910 Pemetrexed Disodium and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01001910 Completed Albert Einstein College of Medicine 2015-01-31
NCT00993655 Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer https://ClinicalTrials.gov/show/NCT00993655 Completed Canadian Cancer Trials Group 2016-03-10
NCT00993616 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin https://ClinicalTrials.gov/show/NCT00993616 Completed National Cancer Institute (NCI) 2012-07-31
NCT00989651 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00989651 Active, not recruiting National Cancer Institute (NCI) 2020-09-01
NCT00989131 Study of Paclitaxel in Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT00989131 Completed Oasmia Pharmaceutical AB 2013-10-31
NCT00959582 Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) https://ClinicalTrials.gov/show/NCT00959582 Completed Merck Sharp & Dohme Corp. 2011-10-31
NCT00954174 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00954174 Active, not recruiting Gynecologic Oncology Group 2019-03-30
NCT00951496 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00951496 Active, not recruiting National Cancer Institute (NCI) 2016-01-11
NCT00880360 A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer https://ClinicalTrials.gov/show/NCT00880360 Completed The University of Texas Health Science Center at San Antonio 2010-04-30
NCT00872989 S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00872989 Completed Southwest Oncology Group 2013-10-31
NCT00857545 OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission https://ClinicalTrials.gov/show/NCT00857545 Completed Gynecologic Oncology Group 2015-09-30
NCT00856180 Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies https://ClinicalTrials.gov/show/NCT00856180 Completed Dana-Farber Cancer Institute 2010-04-30
NCT00850772 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT00850772 Completed Queensland Centre for Gynaecological Cancer 2013-08-31
NCT00842452 Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT00842452 Completed Case Comprehensive Cancer Center 2011-04-30
NCT01673217 Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01673217 Completed Roswell Park Cancer Institute 2011-10-31
NCT03924245 Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers https://ClinicalTrials.gov/show/NCT03924245 Recruiting Vanderbilt-Ingram Cancer Center 2023-09-30
NCT03759600 Japan Phase 2 Study of Niraparib in Patients With Advanced, Relapsed Ovarian Cancer https://ClinicalTrials.gov/show/NCT03759600 Active, not recruiting Takeda 2019-07-01
NCT01853644 Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01853644 Active, not recruiting Northwestern University 2018-10-02
NCT00801320 Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00801320 Active, not recruiting Dana-Farber Cancer Institute 2020-08-31
NCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43) https://ClinicalTrials.gov/show/NCT03740165 Recruiting Merck Sharp & Dohme Corp. 2025-08-08
NCT00803569 Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers https://ClinicalTrials.gov/show/NCT00803569 Completed Ludwig Institute for Cancer Research 2011-01-24
NCT00770536 AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR https://ClinicalTrials.gov/show/NCT00770536 Completed Amgen 2012-01-31
NCT00768144 Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma https://ClinicalTrials.gov/show/NCT00768144 Completed Dana-Farber Cancer Institute 2012-05-31
NCT00721162 Study of Ramucirumab in Ovarian Cancer https://ClinicalTrials.gov/show/NCT00721162 Completed Eli Lilly and Company 2012-05-31
NCT00719303 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00719303 Recruiting Gynecologic Oncology Group 2020-12-31
NCT00702299 Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer https://ClinicalTrials.gov/show/NCT00702299 Completed University of Arizona 2012-01-31
NCT00698451 A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers https://ClinicalTrials.gov/show/NCT00698451 Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2010-10-31
NCT00692900 Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00692900 Completed University of Pittsburgh 2013-06-30
NCT00672295 PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer https://ClinicalTrials.gov/show/NCT00672295 Completed Duke University 2011-09-30
NCT00652119 Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin https://ClinicalTrials.gov/show/NCT00652119 Active, not recruiting Massachusetts General Hospital 2009-08-31
NCT00617773 Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00617773 Completed Recepta Biopharma 2012-06-30
NCT00616941 Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00616941 Completed Ludwig Institute for Cancer Research 2011-06-30
NCT00602277 Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy https://ClinicalTrials.gov/show/NCT00602277 Completed National Cancer Institute (NCI) 2016-08-31
NCT00588237 Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00588237 Completed Memorial Sloan Kettering Cancer Center 2014-11-30
NCT00569673 Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00569673 Completed Gynecologic Oncology Group 2012-01-31
NCT00565851 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00565851 Active, not recruiting National Cancer Institute (NCI) 2019-11-14
NCT00562640 Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) https://ClinicalTrials.gov/show/NCT00562640 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-12-31
NCT00550784 Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00550784 Completed City of Hope Medical Center 2014-10-31
NCT00543049 Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor https://ClinicalTrials.gov/show/NCT00543049 Completed AGO Study Group 2012-06-30
NCT00538031 Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00538031 Active, not recruiting City of Hope Medical Center 2020-12-31
NCT00526617 A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients https://ClinicalTrials.gov/show/NCT00526617 Completed AbbVie 2010-06-30
NCT00520013 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors https://ClinicalTrials.gov/show/NCT00520013 Completed Dana-Farber Cancer Institute 2010-10-31
NCT00517621 Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire https://ClinicalTrials.gov/show/NCT00517621 Completed ARCAGY/ GINECO GROUP 2010-09-30
NCT00515372 Depression Treatment and Screening in Ovarian Cancer Patients https://ClinicalTrials.gov/show/NCT00515372 Active, not recruiting M.D. Anderson Cancer Center 2020-12-31
NCT00504257 Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma https://ClinicalTrials.gov/show/NCT00504257 Completed H. Lee Moffitt Cancer Center and Research Institute 2012-10-31
NCT00501644 Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT00501644 Completed M.D. Anderson Cancer Center 2009-01-31
NCT00483782 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00483782 Completed National Cancer Institute (NCI) NA
NCT00479817 Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00479817 Completed Amgen 2009-08-11
NCT00478452 Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients https://ClinicalTrials.gov/show/NCT00478452 Completed University of Pennsylvania 2008-08-31
NCT00466986 Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer https://ClinicalTrials.gov/show/NCT00466986 Completed Southeastern Gynecologic Oncology 2011-10-31
NCT00466960 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy https://ClinicalTrials.gov/show/NCT00466960 Completed University of Washington 2011-07-31
NCT00459290 Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00459290 Completed Gynecologic Oncology Group 2010-07-31
NCT00443196 Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas https://ClinicalTrials.gov/show/NCT00443196 Completed Pierian Biosciences NA
NCT00436501 VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00436501 Completed National Cancer Institute (NCI) 2011-03-31
NCT00436215 Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00436215 Completed National Institutes of Health Clinical Center (CC) 2014-06-26
NCT00429793 Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00429793 Completed National Cancer Institute (NCI) 2012-01-31
NCT00428610 A Study of Chemotherapy Treatment for Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT00428610 Completed Eli Lilly and Company 2011-02-28
NCT00421889 A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment https://ClinicalTrials.gov/show/NCT00421889 Completed Onxeo 2009-02-28
NCT00391118 Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo (“Sugar Pill”) https://ClinicalTrials.gov/show/NCT00391118 Completed Eli Lilly and Company 2010-04-30
NCT00390234 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma https://ClinicalTrials.gov/show/NCT00390234 Completed National Cancer Institute (NCI) 2011-09-30
NCT00388037 Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00388037 Completed National Cancer Institute (NCI) 2012-01-31
NCT00382811 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT00382811 Completed MEI Pharma, Inc. 2009-04-30
NCT00381888 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer https://ClinicalTrials.gov/show/NCT00381888 Completed Masonic Cancer Center, University of Minnesota 2009-01-31
NCT00357448 Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00357448 Completed University of Washington 2009-11-30
NCT00343044 Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers https://ClinicalTrials.gov/show/NCT00343044 Completed Benaroya Research Institute 2010-01-31
NCT00334893 Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00334893 Completed National Cancer Institute (NCI) 2012-03-31
NCT00318370 Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy https://ClinicalTrials.gov/show/NCT00318370 Completed Morphotek 2010-02-28
NCT00317772 Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00317772 Active, not recruiting M.D. Anderson Cancer Center 2020-09-04
NCT00293293 Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine https://ClinicalTrials.gov/show/NCT00293293 Completed Masonic Cancer Center, University of Minnesota 2009-04-30
NCT00799110 Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod https://ClinicalTrials.gov/show/NCT00799110 Active, not recruiting Dana-Farber Cancer Institute 2020-12-31
NCT00287885 Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer https://ClinicalTrials.gov/show/NCT00287885 Completed Masonic Cancer Center, University of Minnesota 2008-12-31
NCT00281632 A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer https://ClinicalTrials.gov/show/NCT00281632 Completed GlaxoSmithKline 2008-04-30
NCT00278343 Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00278343 Completed National Cancer Institute (NCI) 2010-06-30
NCT00275028 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00275028 Completed National Cancer Institute (NCI) 2010-03-31
NCT00268918 Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients https://ClinicalTrials.gov/show/NCT00268918 Completed Dana-Farber Cancer Institute 2007-01-31
NCT00267696 Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00267696 Completed Ohio State University Comprehensive Cancer Center 2013-09-30
NCT02855944 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients https://ClinicalTrials.gov/show/NCT02855944 Recruiting Clovis Oncology, Inc. 2022-06-30
NCT00263822 Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00263822 Completed European Organisation for Research and Treatment of Cancer - EORTC 2008-02-29
NCT00262990 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00262990 Completed Novartis 2010-02-28
NCT00262847 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00262847 Completed National Cancer Institute (NCI) 2010-11-30
NCT00245050 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer https://ClinicalTrials.gov/show/NCT00245050 Completed Case Comprehensive Cancer Center 2008-04-30
NCT00230542 Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer https://ClinicalTrials.gov/show/NCT00230542 Completed Dana-Farber Cancer Institute 2007-07-31
NCT00226915 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma https://ClinicalTrials.gov/show/NCT00226915 Completed Japanese Gynecologic Oncology Group 2012-06-30
NCT00217555 Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00217555 Completed Fred Hutchinson Cancer Research Center 2006-02-28
NCT00217529 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00217529 Completed Fred Hutchinson Cancer Research Center 2005-11-30
NCT00191646 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy https://ClinicalTrials.gov/show/NCT00191646 Completed Eli Lilly and Company 2009-08-31
NCT00191607 A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. https://ClinicalTrials.gov/show/NCT00191607 Completed Eli Lilly and Company NA
NCT00189566 Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse https://ClinicalTrials.gov/show/NCT00189566 Completed ARCAGY/ GINECO GROUP NA
NCT00189553 Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse https://ClinicalTrials.gov/show/NCT00189553 Completed ARCAGY/ GINECO GROUP 2009-01-31
NCT00189358 A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy https://ClinicalTrials.gov/show/NCT00189358 Completed AGO Study Group NA
NCT00189345 Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients https://ClinicalTrials.gov/show/NCT00189345 Completed AGO Study Group NA
NCT00182767 Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer https://ClinicalTrials.gov/show/NCT00182767 Completed National Cancer Institute (NCI) 2012-04-30
NCT00157573 GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer https://ClinicalTrials.gov/show/NCT00157573 Completed Massachusetts General Hospital 2008-10-31
NCT00157560 Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma https://ClinicalTrials.gov/show/NCT00157560 Completed Massachusetts General Hospital 2006-11-30
NCT00138242 Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00138242 Completed National Cancer Institute (NCI) NA
NCT00114166 Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00114166 Completed Gynecologic Oncology Group 2011-01-31
NCT00112957 Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00112957 Completed Ludwig Institute for Cancer Research 2009-05-31
NCT00112086 OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 https://ClinicalTrials.gov/show/NCT00112086 Completed Japan Clinical Oncology Group 2007-02-28
NCT00108745 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00108745 Active, not recruiting Gynecologic Oncology Group 2022-01-01
NCT00103545 Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response https://ClinicalTrials.gov/show/NCT00103545 Completed AGO Study Group NA
NCT00098878 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00098878 Completed National Cancer Institute (NCI) 2010-07-31
NCT00096993 A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00096993 Completed Genentech, Inc. 2007-09-30
NCT00096239 CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00096239 Completed National Cancer Institute (NCI) NA
NCT00096200 Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00096200 Completed National Cancer Institute (NCI) 2011-04-30
NCT00091377 Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00091377 Completed MEI Pharma, Inc. 2007-12-31
NCT00002960 SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) https://ClinicalTrials.gov/show/NCT00002960 Completed Merck Sharp & Dohme Corp. 2000-07-31
NCT00003358 Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00003358 Completed Memorial Sloan Kettering Cancer Center 2001-01-31
NCT00004060 Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00004060 Completed Daiichi Sankyo, Inc. 2000-09-30
NCT00006041 Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00006041 Completed Memorial Sloan Kettering Cancer Center 2002-02-28
NCT00006235 Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00006235 Completed Gynecologic Oncology Group 2006-02-28
NCT00085358 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) https://ClinicalTrials.gov/show/NCT00085358 Completed National Cancer Institute (NCI) 2011-05-31
NCT00002538 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers https://ClinicalTrials.gov/show/NCT00002538 Completed Gynecologic Oncology Group 2010-03-31
NCT00004012 Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00004012 Completed Memorial Sloan Kettering Cancer Center 2000-12-31
NCT00003944 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00003944 Completed Fox Chase Cancer Center 1999-12-31
NCT00019552 Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00019552 Completed National Cancer Institute (NCI) NA
NCT00004082 Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors https://ClinicalTrials.gov/show/NCT00004082 Completed National Cancer Institute (NCI) 2003-09-30
NCT00002600 Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer https://ClinicalTrials.gov/show/NCT00002600 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2001-07-25
NCT00003967 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00003967 Completed Gynecologic Oncology Group 2006-04-30
NCT00003345 Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00003345 Completed Memorial Sloan Kettering Cancer Center 2001-10-31
NCT00079430 Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00079430 Completed National Cancer Institute (NCI) 2011-05-31
NCT00014690 ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00014690 Completed National Cancer Institute (NCI) NA
NCT00010179 Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer https://ClinicalTrials.gov/show/NCT00010179 Completed Canadian Cancer Trials Group 2002-10-22
NCT00003120 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission https://ClinicalTrials.gov/show/NCT00003120 Completed Southwest Oncology Group 2003-06-30
NCT00021034 Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00021034 Completed Memorial Sloan Kettering Cancer Center 2001-08-31
NCT00003334 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract https://ClinicalTrials.gov/show/NCT00003334 Completed NYU Langone Health 2001-12-31
NCT00006454 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer https://ClinicalTrials.gov/show/NCT00006454 Completed AGO Study Group 2006-08-31
NCT00022347 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00022347 Completed National Cancer Institute (NCI) 2004-04-30
NCT00075712 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00075712 Completed National Cancer Institute (NCI) NA
NCT00074867 Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00074867 Completed Pfizer NA
NCT00017017 CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00017017 Completed National Cancer Institute (NCI) 2003-02-28
NCT00012090 Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum https://ClinicalTrials.gov/show/NCT00012090 Completed Memorial Sloan Kettering Cancer Center 2004-04-30
NCT00072267 UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00072267 Completed University Health Network, Toronto 2005-04-30
NCT00004074 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu https://ClinicalTrials.gov/show/NCT00004074 Completed National Cancer Institute (NCI) 2009-02-28
NCT00066729 Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00066729 Completed National Cancer Institute (NCI) 2006-07-31
NCT00066651 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT00066651 Completed National Cancer Institute (NCI) NA
NCT00066456 Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00066456 Completed Gynecologic Oncology Group 2010-07-31
NCT00031954 Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00031954 Completed AGO Study Group 2004-04-30
NCT00063401 Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00063401 Completed Eli Lilly and Company 2006-06-30
NCT00030446 Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00030446 Completed Canadian Cancer Trials Group 2005-02-11
NCT00061308 Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00061308 Completed GlaxoSmithKline 2004-09-30
NCT00060359 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00060359 Completed Gynecologic Oncology Group 2009-01-31
NCT00059787 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma https://ClinicalTrials.gov/show/NCT00059787 Completed National Cancer Institute (NCI) 2010-05-31
NCT00059618 PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00059618 Completed M.D. Anderson Cancer Center 2007-04-30
NCT00058435 Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00058435 Completed Memorial Sloan Kettering Cancer Center 2004-03-31
NCT00055614 Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00055614 Completed National Cancer Institute (NCI) NA
NCT00052468 Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00052468 Completed AGO Study Group 2009-07-31
NCT00049556 Gefitinib in Treating Patients With Cervical Cancer https://ClinicalTrials.gov/show/NCT00049556 Completed National Cancer Institute (NCI) NA
NCT00045175 UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00045175 Completed University Health Network, Toronto 2013-06-30
NCT00041080 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00041080 Completed National Cancer Institute (NCI) 2011-01-31
NCT00039585 Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor https://ClinicalTrials.gov/show/NCT00039585 Completed National Cancer Institute (NCI) 2006-02-28
NCT00033605 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis https://ClinicalTrials.gov/show/NCT00033605 Completed Alliance for Clinical Trials in Oncology 2006-07-31
NCT00032162 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer https://ClinicalTrials.gov/show/NCT00032162 Completed AGO Study Group 2005-05-31
NCT00028912 Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00028912 Completed National Cancer Institute (NCI) NA
NCT00028743 Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00028743 Completed Canadian Cancer Trials Group 2008-03-05
NCT00019461 Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00019461 Completed National Cancer Institute (NCI) NA
NCT00008138 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer https://ClinicalTrials.gov/show/NCT00008138 Completed Southwest Oncology Group 2009-09-30
NCT00006981 Immunotoxin Therapy in Treating Patients With Advanced Cancer https://ClinicalTrials.gov/show/NCT00006981 Completed National Cancer Institute (NCI) NA
NCT00006942 Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00006942 Completed National Cancer Institute (NCI) 2004-03-31
NCT00006391 Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00006391 Completed NYU Langone Health 2004-11-30
NCT00004934 Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00004934 Completed National Cancer Institute (NCI) NA
NCT00003896 S9912 Combination Chemo in Stage III Ovarian Cancer, https://ClinicalTrials.gov/show/NCT00003896 Completed Southwest Oncology Group 2008-02-29
NCT00003636 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00003636 Completed European Organisation for Research and Treatment of Cancer - EORTC 2009-01-31
NCT00003385 Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00003385 Completed Gynecologic Oncology Group 2007-01-31
NCT00002895 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00002895 Completed National Cancer Institute (NCI) NA
NCT00006155 SU5416 and Carboplatin to Treat Ovarian Cancer https://ClinicalTrials.gov/show/NCT00006155 Completed National Institutes of Health Clinical Center (CC) NA
NCT00035100 EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00035100 Completed Novartis 2003-06-30
NCT00126542 Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer https://ClinicalTrials.gov/show/NCT00126542 Completed National Cancer Institute (NCI) 2007-01-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03367260 The Treatment Preferences of Women Diagnosed With Ovarian Cancer https://ClinicalTrials.gov/show/NCT03367260 Completed Duke University 2019-01-04
NCT03189108 Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors https://ClinicalTrials.gov/show/NCT03189108 Enrolling by invitation National Institutes of Health Clinical Center (CC) 2027-01-04
NCT03159572 Homologous Recombination Inquiry Through Ovarian Malignancy Investigations https://ClinicalTrials.gov/show/NCT03159572 Active, not recruiting Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 2021-09-30
NCT03000192 HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life https://ClinicalTrials.gov/show/NCT03000192 Active, not recruiting University Hospital Southampton NHS Foundation Trust 2020-12-31
NCT02928549 Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study https://ClinicalTrials.gov/show/NCT02928549 Completed Memorial Sloan Kettering Cancer Center 2019-08-26
NCT02824328 A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers https://ClinicalTrials.gov/show/NCT02824328 Active, not recruiting Duke University 2020-12-31
NCT02973750 Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer https://ClinicalTrials.gov/show/NCT02973750 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2021-01-31
NCT00086567 Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers https://ClinicalTrials.gov/show/NCT00086567 Completed National Institutes of Health Clinical Center (CC) NA
NCT02489058 A Study of Long-Term Responders on Olaparib https://ClinicalTrials.gov/show/NCT02489058 Recruiting University Health Network, Toronto 2020-07-31
NCT02343510 Detection of Chlamydia DNA by Polymerase Chain Reaction in Primary Tubal and Ovarian Cancers Tissues : a Pilot Study https://ClinicalTrials.gov/show/NCT02343510 Completed Ain Shams University 2017-03-31
NCT02122588 OVArian Cancer Non-Interventional Study - OVATAR https://ClinicalTrials.gov/show/NCT02122588 Completed AstraZeneca 2018-05-31
NCT01276574 Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT https://ClinicalTrials.gov/show/NCT01276574 Active, not recruiting Turku University Hospital 2020-12-31
NCT01932125 An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01932125 Recruiting Hoffmann-La Roche 2020-11-30
NCT01851928 Validation of a Nutrition Screening Tool https://ClinicalTrials.gov/show/NCT01851928 Completed Royal Marsden NHS Foundation Trust 2012-09-30
NCT01591772 Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer https://ClinicalTrials.gov/show/NCT01591772 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-04-30
NCT01582906 A Survivorship Care Plan for Gynaecological Cancer Patients https://ClinicalTrials.gov/show/NCT01582906 Completed Royal Marsden NHS Foundation Trust 2014-03-31
NCT01471483 Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer https://ClinicalTrials.gov/show/NCT01471483 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-11-30
NCT01372787 Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01372787 Active, not recruiting Gynecologic Oncology Group 2014-01-31
NCT01370122 Pelvic Floor Disorders in Survivors of Gynecologic Malignancies https://ClinicalTrials.gov/show/NCT01370122 Completed Abramson Cancer Center of the University of Pennsylvania 2012-10-31
NCT01366183 Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01366183 Active, not recruiting Gynecologic Oncology Group 2019-12-31
NCT04295577 Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR https://ClinicalTrials.gov/show/NCT04295577 Active, not recruiting Royal Marsden NHS Foundation Trust 2022-02-03
NCT03921658 The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer https://ClinicalTrials.gov/show/NCT03921658 Recruiting University of Minnesota 2022-10-31
NCT03604653 Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers https://ClinicalTrials.gov/show/NCT03604653 Recruiting Holy Name Medical Center, Inc. 2021-05-31
NCT03593681 Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy https://ClinicalTrials.gov/show/NCT03593681 Completed Boston Scientific Corporation 2020-02-14
NCT03471572 Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India https://ClinicalTrials.gov/show/NCT03471572 Completed AstraZeneca 2018-12-21
NCT01216813 Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer https://ClinicalTrials.gov/show/NCT01216813 Completed National Cancer Institute (NCI) 2010-10-31
NCT01080521 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy https://ClinicalTrials.gov/show/NCT01080521 Completed Gynecologic Oncology Group 2012-01-31
NCT01048814 Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases https://ClinicalTrials.gov/show/NCT01048814 Completed Precision Therapeutics 2011-06-30
NCT00897442 Collecting Tumor Samples From Patients With Gynecological Tumors https://ClinicalTrials.gov/show/NCT00897442 Completed Gynecologic Oncology Group 2016-01-31
NCT00870233 Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life https://ClinicalTrials.gov/show/NCT00870233 Completed Memorial Sloan Kettering Cancer Center 2018-02-12
NCT04204811 Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy https://ClinicalTrials.gov/show/NCT04204811 Recruiting Memorial Sloan Kettering Cancer Center 2020-12-16
NCT00499512 Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00499512 Active, not recruiting M.D. Anderson Cancer Center 2020-08-31
NCT00415207 Pharmacogenomics of Paclitaxel in Ovarian Cancer https://ClinicalTrials.gov/show/NCT00415207 Completed University of Southern Denmark 2008-08-31
NCT00415181 Pharmacogenomics of Paclitaxel in Ovarian Cancer https://ClinicalTrials.gov/show/NCT00415181 Completed University of Southern Denmark 2009-01-31
NCT00295945 Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer https://ClinicalTrials.gov/show/NCT00295945 Completed University of California, San Francisco 2008-04-30
NCT00005095 Specimen and Data Study for Ovarian Cancer Early Detection and Prevention https://ClinicalTrials.gov/show/NCT00005095 Recruiting Northwestern University 2020-12-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT04027868 Genomic BRCA and Extensive ovArian Cancer Testing https://ClinicalTrials.gov/show/NCT04027868 Recruiting ARCAGY/ GINECO GROUP 2029-12-31